临床肿瘤学杂志 ›› 2019, Vol. 24 ›› Issue (2): 102-107.

• • 上一篇    下一篇

miR-582-5p靶向抑制Rab27a对肺癌细胞生物学行为的影响

  

  1. 610000  成都  核工业四一六医院 成都医学院第二附属医院肿瘤科

  • 收稿日期:2018-07-27 修回日期:2018-10-13 出版日期:2019-02-28 发布日期:2019-03-18

Targeted inhibition of Rab27a by microRNA-582-5p on biological behavior of lung cancer cells

  1. Department of Oncology, the Second Affiliated Hospital of Chengdu Medical College, Nuclear Industry 416 Hospital, Chengdu 610000, China
  • Received:2018-07-27 Revised:2018-10-13 Online:2019-02-28 Published:2019-03-18

摘要: 目的  探讨microRNA-582-5p(miR-582-5p)在非小细胞肺癌(NSCLC)中表达及其对A549细胞增殖、侵袭的影响,以及对Rab27a基因的靶向调控作用。方法  采用实时荧光定量PCR(QPCR)检测33例行手术治疗的NSCLC患者的癌组织、对应癌旁组织以及A549细胞株、人正常支气管肺上皮细胞株BEAS-2B中miR-582-5p的表达水平。采用miR-582-5p inhibitor(anti-miR-582-5p)和miR-582-5p mimics(mim-miR-582-5p)转染A549细胞,另分别转染miRNA inhibitor无关系列(anti-NC)和miRNA mimics无关系列(mim-NC)作阴性对照。采用双荧光素酶报告实验验证Rab27a与miR-582-5p的关系。采用MTT法和Transwell小室法检测各组细胞增殖、侵袭能力;采用QPCR和Western blotting检测各组A549细胞中Rab27a mRNA和蛋白水平。结果  NSCLC组织和癌旁组织中miR-582-5p表达水平分别为0.26±0.09和0.83±0.10;A549细胞株和BEAS-2B细胞株中miR-582-5p表达水平分别为0.63±0.08和1.17±0.09,差异均有统计学意义(P<0.05)。anti-miR-582-5p组A549细胞24、48、72、96 h后的增殖率分别为(115.68±4.34)%、(130.48±5.48)%、(138.95±5.55)%、(147.03±5.69)%,明显高于anti-NC组;mim-miR-582-5p组A549细胞24、48、72、96 h后的增殖率分别为(91.31±4.18)%、(86.74±3.23)%、(79.45±3.20)%、(75.22±4.09)%,明显低于mim-NC组,差异均有统计学意义(P<0.05)。Transwell小室结果显示,anti-miR-582-5p组A549细胞侵袭数为189±19,明显高于anti-NC组;mim-miR-582-5p组A549细胞侵袭数为55±8,明显低于mim-NC组,差异均有统计学意义(P<0.05)。miR-582-5p可抑制野生型Rab27a 3’-UTR报告基因载体的荧光素酶活性,而对突变型Rab27a 3’-UTR的荧光素酶活性无影响。anti-miR-582-5p组A549细胞Rab27a mRNA和蛋白表达水平分别为2.01±0.29和0.85±0.12,高于anti-NC组;mimi-miR-582-5p组A549细胞Rab27a mRNA和蛋白表达水平分别为0.35±0.08和0.21±0.05,明显低于mim-NC组,差异均有统计学意义(P<0.05)。结论  上调miR-582-5p表达可抑制Rab27a表达,从而抑制肺癌A549细胞增殖、侵袭活性,miR-582-5p有望成为肺癌新的治疗靶点。

关键词: 非小细胞肺癌, 微小RNA, miR-582-5p, Rab27a, 增殖, 侵袭 ,  ,  ,  ,  

Abstract:

Objective  To investigate the expression of microRNA-582-5p (miR-582-5p) in non-small cell lung cancer (NSCLC) and its effect on proliferation and invasion of A549 cells, as well as the targeting regulation of Rab27a gene. Methods  The expression of miR-582-5p in 33 NSCLC tissues and adjacent tissues, A549 cell line and human normal bronchopulmonary epithelial cell line BEAS-2B was detected by real-time fluorescence quantitative polymerase chain reaction (QPCR). MiR-582-5p inhibitor (anti-miR-582-5p) and miR-582-5p mimics (mim-miR-582-5p) transfected into A549 cells, and anti-NC and mim-NC were used as negative control. The relationship between Rab27a and miR-582-5p was validated by double luciferase reporter assay. MTT assay and Transwell chamber assay were used to detect the proliferation and invasion ability of A549 cells, QPCR and Western blotting were used to detect the expression of Rab27a gene and protein. Results  The expression of miR-582-5p in NSCLC tissues and adjacent tissues were 0.26±0.09 and 0.83±0.10, respectively. The expression of miR-582-5p in A549 cell lines and BEAS-2B cell lines were 0.63±0.08 and 1.17±0.09, respectively, with statistical significance (P<0.05). The proliferation rates of A549 cells in anti-miR-582-5p group after 24, 48, 72 and 96 hours were (115.68±4.34)%, (130.48±5.48)%, (138.95±5.55)%, (147.03±5.69)%, respectively, which were significantly higher than those in anti-NC group (P<0.05). The proliferation rates of A549 cells in mim-miR-582-5p group after 24, 48, 72 and 96 hours were (91.31±4.18)%, (86.74±3.23)%, (79.45±3.20)%, (75.22±4.09)% respectively, which were significantly lower than those in mim-NC group (P<0.05). Transwell chamber results showed that the invasion number of A549 cells in anti-miR-582-5p group was 189±19, which was significantly higher than that in anti-NC group; the invasion number of A549 cells in mim-miR-582-5p group was 55±8, which was significantly lower than that in mim-NC group (P<0.05). MiR-582-5p inhibited the luciferase activity of wild type Rab27a 3’-UTR reporter gene vector, but had no effect on mutant Rab27a 3’-UTR luciferase activity. The expression of Rab27a mRNA and protein in anti-miR-582-5p group were (2.01±0.29) and (0.85±0.12), which were higher than anti-NC group (P<0.05). The expression of Rab27a mRNA and protein in mim-miR-582-5p group were (0.35±0.08) and (0.21±0.05), which were lower than mim-NC group (P<0.05). Conclusion  Up-regulation of the expression of miR-582-5p can inhibit the expression of Rab27a, thus inhibiting the proliferation and invasive activity of lung cancer A549 cells. MicroRNA-582-5p is expected to become a new therapeutic target for lung cancer.

Key words: Non-small cell lung cancer(NSCLC), microRNAs, miR-582-5p, Rab27a, Proliferation, Invision

中图分类号: 

  • R734.2
[1] 高晓会, 张亚利, 张治业, 郭艳珍, 陈小兵. miR-21靶向Atg5对非小细胞肺癌A549细胞自噬调控促进细胞增殖、迁移和侵袭的实验研究[J]. 临床肿瘤学杂志, 2019, 24(2): 97-101.
[2] 张 宁, 卢创新, 务 森, 何 苡, 魏 立.

miR-138-5p在非小细胞肺癌中的表达及临床意义 [J]. 临床肿瘤学杂志, 2019, 24(2): 149-152.

[3] 葛 琴, 钱 霞, 谢国栋, 蔡 晶, 杨百霞, 吴建亭, 赵季忠, 崔娟娟, 朱兴华, 储春霞. EGFR和TGF-α在肺癌细胞放疗增敏中的作用[J]. 临床肿瘤学杂志, 2019, 24(2): 145-148.
[4] 杨三虎, 文苗苗, 张志培, 李维妙, 杨 锋, 李小飞.

非小细胞肺癌ROS1突变与EGFR突变及临床病理特征的关系 [J]. 临床肿瘤学杂志, 2019, 24(2): 175-178.

[5] 秦博宇, 宋 琪, 孙胜杰, 孙 琼, 陶 然, 焦顺昌.

外泌体在非小细胞肺癌获得性耐药中的研究进展 [J]. 临床肿瘤学杂志, 2019, 24(2): 179-182.

[6] 魏丹凤, 郭元彪, 王战豪, 朱义芳.  四川地区非小细胞肺癌患者EGFR基因突变分型与临床病理特征的相关性分析[J]. 临床肿瘤学杂志, 2018, 23(10): 915-919.
[7] 章余妹, 邵莉.  成人睾丸卵黄囊瘤1例[J]. 临床肿瘤学杂志, 2018, 23(10): 957-958.
[8] 张超, 牛意, 张洁, 姚学敏, 高鹏, 刘美月, 魏晓梅, 杨朝, 刘春玲, 张月恒, 李宏民, 孙国贵.  

miR-1253对肺腺癌细胞增殖与迁移侵袭能力的影响 [J]. 临床肿瘤学杂志, 2018, 23(10): 865-869.

[9] 王海涛, 杨敬贤, 率胜胜. 不同工作年限放疗技师对老年Ⅲ期非小细胞肺癌调强放疗疗效的影响[J]. 临床肿瘤学杂志, 2018, 23(5): 449-452.
[10] 刘华丽, 阮 鹏, 彭 敏, 袁静萍, 宋启斌, 韩 光. 阿帕替尼联合脑部放疗同步替莫唑胺治疗非典型肺类癌脑转移1例[J]. 临床肿瘤学杂志, 2018, 23(5): 476-478.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 周文杰1,蒋敬庭1,李 敏1,邓海峰1,徐 斌1,吴昌平. CIK细胞及上清液抗胃癌细胞株SGC-7901活性的研究*[J]. 临床肿瘤学杂志, 2009, 14(4): 297 .
[2]  徐 燕,王 丹 综述,梁志清 审校. 肿瘤血管异质性的研究进展[J]. 临床肿瘤学杂志, 2009, 14(9): 852 .
[3] 张俊凯,潘佩玲,吴颖猛,萧剑军,彭杰文. FOLFOX6方案治疗晚期原发性肝癌的临床观察[J]. 临床肿瘤学杂志, 2010, 15(1): 70 .
[4] 张宏英,陈力舟,林 敏,吕 骁
. Askin瘤报告并文献复习[J]. 临床肿瘤学杂志, 2010, 15(2): 166 .
[5] 秦健勇,曾波航,江素华2. 非小细胞肺癌组织S100、CD83阳性树突状细胞的临床意义[J]. 临床肿瘤学杂志, 2010, 15(4): 315 .
[6] 李 丽1,2,孔 燕1,2,李海夫1,2,于玮玮1,2,代 杰1,2,迟志宏1,2,斯 璐1,2,盛锡楠1,2,崔传亮1,2,郭 军1,2. 262例中国人黑色素瘤C-KIT基因扩增分析[J]. 临床肿瘤学杂志, 2010, 15(5): 385 .
[7] 何平平,戈 伟. 奈达铂单药联合放疗治疗鼻咽癌和食管癌的临床观察[J]. 临床肿瘤学杂志, 2010, 15(5): 444 .
[8] 张宏伟1,叶 芳2,纪 元3,侯英勇3,陈君雪4,朱 玮4,刘天舒5,金 文5,王 红4,曾昭冲6,石洪成7,刘 娟6. 年轻乳腺癌患者的诊治[J]. 临床肿瘤学杂志, 2011, 16(1): 93 .
[9] 戚晓军,刘 丁,姜宇东. 紫杉醇联合顺铂动脉栓塞治疗复发宫颈癌的临床研究[J]. 临床肿瘤学杂志, 2011, 16(2): 162 .
[10] 刘志祥1,姚忠红2,李瑞明1,王晓勋1. NS-398对乳腺癌细胞MCF-7增殖和凋亡的影响及其作用机制[J]. 临床肿瘤学杂志, 2011, 16(3): 216 .